Eli Lilly announced the Food and Drug Administration has issued a complete response letter for the mirikizumab biologic license application for the treatment of ulcerative colitis. In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data package, safety, or label for the medicine, the company said in a statement. "We remain confident in mirikizumab’s pivotal Phase 3 clinical data and its potential to help people with ulcerative colitis," said Patrik Jonsson, Lilly executive vice president, president of Lilly Immunology and Lilly USA, and chief customer officer. "We are working diligently with the FDA and hope to launch mirikizumab in the U.S. as soon as possible."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly price target lowered to $392 from $395 at Guggenheim
- Eli Lilly price target raised to $448 from $444 at Morgan Stanley
- Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports
- JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data
- TD Cowen pharmaceuticals analysts to hold analyst/industry conference call